Anthos' detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer's failed? - Endpoints News
Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in major/clinically relevant bleeds at 150mg dose
Comments